Fig. 7.

HSP22 deficiency offsets MitoTEMPO-inhibited endothelial injury under hyperglycemic conditionsin vitro. HUVECs were transfected with negative control siRNA (NC siRNA) or HSP22 siRNA for 48 h and then treated with high glucose with/without MitoTEMPO (1 μM) for 24 h. A) Cells in 96-well plates were stained with Cell Counting Kit-8 (CCK8) to evaluate cell viability. n = 3. B) Cytotoxicity was measured by LDH release in the cell media. n = 3. C) Adhesion of nonstimulated PBMCs to stimulated HUVECs was quantified. n = 3. D) mRNA expression of ICAM-1 and VCAM-1 was determined by RT-PCR. n = 3. E) Endothelial cell activation-related cytokines were examined by RT-PCR. n = 3. ^*P < 0.05 vs. NC-NG; ^#P < 0.05 vs. HG-MitoTEMPO.